logo
ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

IRVINE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2025 and provided a corporate strategic update.
First Quarter 2025 and Subsequent Highlights
On July 8, 2024, ReShape Lifesciences Inc. entered into a definitive merger agreement with Vyome, under which ReShape and Vyome will combine in an all-stock transaction. At the closing of the merger, ReShape will be renamed Vyome Holdings, Inc. and expects to trade under the Nasdaq ticker symbol 'HIND,' representing the company's alignment with the U.S.-India relationship. The board of directors of the combined company will be comprised of six directors designated by Vyome and one director designated by ReShape, and executive management of the combined company will consist of Vyome's executive officers.
Simultaneously with the execution of the merger agreement, ReShape entered into an asset purchase agreement with Biorad, which was amended on April 25, 2025, which is party to a previously disclosed exclusive license agreement with ReShape for ReShape's Obalon® Gastric Balloon System. Pursuant to the asset purchase agreement, ReShape will sell substantially all of its assets to Biorad (or an affiliate thereof), including ReShape's Lap-Band® System, Obalon® Gastric Balloon System and the Diabetes Bloc-Stim Neuromodulation™ (DBSN™) System (but excluding cash), and Biorad will assume substantially all of ReShape's liabilities. The cash purchase price under the asset purchase agreement will count toward ReShape's net cash for purposes of determining the post-merger ownership allocation between ReShape and Vyome stockholders under the merger agreement.
'The first quarter of 2025 and the months that followed have marked a period of strong momentum for ReShape, both operationally and strategically,' stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences®. 'We continued to expand access to our portfolio of physician-led, minimally invasive weight-loss solutions, highlighted by a new distribution agreement with Liaison Medical to launch our enhanced Lap-Band® 2.0 FLEX to the Canadian market. This partnership, following our Health Canada approval in late 2024, is a significant milestone in delivering effective, less-invasive alternatives to bariatric surgery to broader global patient base. We also expanded our product portfolio through an exclusive U.S. distribution agreement for Motion Informatics' next-generation neuromuscular rehabilitation devices, further broadening our portfolio of innovative medical devices.
'At the same time, we strengthened our leadership in diabetes innovation by presenting promising pre-clinical data on our Diabetes Neuromodulation device at the 12th Annual Minnesota Neuromodulation Symposium, in a featured poster presentation, showcasing the potential of our proprietary vagus neuromodulation technology platform. Further strengthening our position, the Diabetes Neuromodulation system received significant intellectual property protection, including multiple Notices of Allowance from the USPTO and a pivotal international patent from the Israel Patent Office. These patents extend our intellectual property coverage through at least 2039, underscoring our leadership in addressing both Type 1 and Type 2 diabetes through neuromodulation and its close association with obesity. We also received a Notice of Allowance for our intragastric device patent, which covers a next-generation, self-deflating, swallowable balloon system—an important addition to our metabolic health platform. As our patent portfolio grows, we remain committed to protecting our position and, when appropriate, will pursue strategic, non-dilutive funding to support this objective.'
Mr. Hickey concluded, 'The successful completion of our $6.0 million public offering in February strengthens our financial foundation as we continue to execute on our growth initiatives. Finally, we are making continued progress toward finalizing our merger with Vyome and the asset sale to Biorad Medisys. The S-4 was recently declared effective and we are working to set the record date in the near future. Our Board unanimously supports this transformative transaction, which we believe will unlock long-term value for shareholders and drive accelerated growth for the newly combined company.'
First Quarter Ended March 31, 2025, Financial and Operating Results
Revenue $1.1 million for the three months ended March 31, 2025, which represents a contraction of 42.7%, or $0.8 million compared to the same period in 2024. This primarily resulted from a decrease in sales volume primarily due to GLP-1 pharmaceutical weight-loss alternatives as well as a temporary pause in DTC marketing programs.
Gross Profit for the three months ended March 31, 2025 and 2024, was $0.7 million, and $1.2 million, respectively. Gross profit as a percentage of total revenue for the three months ended March 31, 2025, was 61.2% compared to 59.9% for the same period in 2024. The increase in gross profit percentage is due to the reduction in overhead related costs, primarily payroll.
Sales and Marketing Expenses for the three months ended March 31, 2025, decreased by $0.5 million, or 48.1%, to $0.5 million, compared to $1.0 million for the same period in 2024. The decrease is primarily due to a decrease in advertising and marketing expenses, including consulting and professional marketing services.
General and Administrative Expenses for the three months ended March 31, 2025, decreased by approximately $0.3 million, or 13.1%, to $1.6 million, compared to $1.9 million for the same period in 2024. The decrease is primarily due to a $0.4 million reduction in general legal, audit, and other professional fees, as the Company reduced its reliance on consultants and professional services to conserve cash.
Research and Development Expenses for the three months ended March 31, 2025, decreased by $0.1 million, or 24.8% to $0.4 million, compared to approximately $0.5 million for the same period in the prior year.
Transaction Costs for the three months ended March 31, 2025, were $0.4 million. These expenses primarily consisted of legal and audit-related fees incurred in connection with the Company's pending merger and asset sale.
Gain on changes in fair value of liability warrants for the three months ended March 31, 2025 of $3.7 million is related to the change in fair value of liability-classified warrants issued in connection with the Company's February 2025 public offering. The gain recognized in the quarter reflects the decrease in the fair value of the warrants between the issuance date and March 31, 2025.
Cash and Cash Equivalents as of March 31, 2025 were $2.6 million, including restricted cash.
About ReShape Lifesciences®
ReShape Lifesciences® is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational vagal neuromodulation system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
Non-GAAP Disclosures
In addition to the financial information prepared in conformity with GAAP, we provide certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results.
Management believes that the presentation of this non-GAAP financial information provides investors with greater transparency and facilitates comparison of operating results across a broad spectrum of companies with varying capital structures, compensation strategies, and amortization methods, which provides a more complete understanding of our financial performance, competitive position, and prospects for the future. However, the non-GAAP financial measures presented in this release have certain limitations in that they do not reflect all of the costs associated with the operations of our business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the company may be different from similarly named non-GAAP financial measures used by other companies.
Adjusted EBITDA
Management uses Adjusted EBITDA in its evaluation of the company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Adjusted EBITDA is defined as net loss before interest, taxes, depreciation and amortization, stock-based compensation, and other one-time costs. Management uses Adjusted EBITDA in its evaluation of the company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the company may be different from similarly named non-GAAP financial measures used by other companies.
Additional Information
In connection with the proposed Merger and Asset Sale, ReShape plans to file with the Securities and Exchange Commission (the 'SEC') and mail or otherwise provide to its stockholders a joint proxy statement/prospectus and other relevant documents in connection with the proposed Merger and Asset Sale. Before making a voting decision, ReShape's stockholders are urged to read the joint proxy statement/prospectus and any other documents filed by ReShape with the SEC in connection with the proposed Merger and Asset Sale or incorporated by reference therein carefully and in their entirety when they become available because they will contain important information about ReShape, Vyome and the proposed transactions. Investors and stockholders may obtain a free copy of these materials (when they are available) and other documents filed by ReShape with the SEC at the SEC's website at www.sec.gov, at ReShape's website at www.reshapelifesciences.com, or by sending a written request to ReShape at 18 Technology Drive, Suite 110, Irvine, California 92618, Attention: Corporate Secretary.
Participants in the Solicitation
This document does not constitute a solicitation of proxy, an offer to purchase or a solicitation of an offer to sell any securities of ReShape and its directors, executive officers and certain other members of management and employees may be deemed to be participants in soliciting proxies from its stockholders in connection with the proposed Merger and Asset Sale. Information regarding the persons who may, under the rules of the SEC, be considered to be participants in the solicitation of ReShape's stockholders in connection with the proposed Merger and Asset Sale will be set forth in joint proxy statement/prospectus if and when it is filed with the SEC by ReShape and Vyome. Security holders may obtain information regarding the names, affiliations and interests of ReShape's directors and officers in ReShape's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on April 4, 2025. To the extent the holdings of ReShape securities by ReShape's directors and executive officers have changed since the amounts set forth in ReShape's proxy statement for its most recent annual meeting of stockholders, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding these individuals and any direct or indirect interests they may have in the proposed Merger and Asset Sale will be set forth in the joint proxy statement/prospectus when and if it is filed with the SEC in connection with the proposed Merger and Asset Sale, at ReShape's website at www.reshapelifesciences.com.
Forward-Looking Statements
Certain statements contained in this filing may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Merger and Asset Sale and the ability to consummate the Merger and Asset Sale. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'believes,' 'plans,' 'anticipates,' 'projects,' 'estimates,' 'expects,' 'intends,' 'strategy,' 'future,' 'opportunity,' 'may,' 'will,' 'should,' 'could,' 'potential,' or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and ReShape undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: (1) ReShape may be unable to obtain stockholder approval as required for the proposed Merger and Asset Sale; (2) conditions to the closing of the Merger or Asset Sale may not be satisfied; (3) the Merger and Asset Sale may involve unexpected costs, liabilities or delays; (4) ReShape's business may suffer as a result of uncertainty surrounding the Merger and Asset Sale; (5) the outcome of any legal proceedings related to the Merger or Asset Sale; (6) ReShape may be adversely affected by other economic, business, and/or competitive factors; (7) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement or Asset Purchase Agreement; (8) the effect of the announcement of the Merger and Asset Purchase Agreement on the ability of ReShape to retain key personnel and maintain relationships with customers, suppliers and others with whom ReShape does business, or on ReShape's operating results and business generally; and (9) other risks to consummation of the Merger and Asset Sale, including the risk that the Merger and Asset Sale will not be consummated within the expected time period or at all. Additional factors that may affect the future results of ReShape are set forth in its filings with the SEC, including ReShape's most recently filed Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on the SEC's website at www.sec.gov, specifically under the heading 'Risk Factors.' The risks and uncertainties described above and in ReShape's most recent Annual Report on Form 10-K are not exclusive and further information concerning ReShape and its business, including factors that potentially could materially affect its business, financial condition or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Readers should also carefully review the risk factors described in other documents that ReShape files from time to time with the SEC. The forward-looking statements in these materials speak only as of the date of these materials. Except as required by law, ReShape assumes no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
CONTACTS:
ReShape Lifesciences Contact:
Paul F. Hickey
President and Chief Executive Officer
949-276-7223
[email protected]
Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
[email protected]
The following table contains a reconciliation of GAAP net income (loss) to Adjusted EBITDA attributable to common stockholders for the three months ended March 31, 2025 and 2024 (in thousands):

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Musk-Trump Space Showdown Sends Rocket Lab Shares Soaring
Musk-Trump Space Showdown Sends Rocket Lab Shares Soaring

Yahoo

time16 minutes ago

  • Yahoo

Musk-Trump Space Showdown Sends Rocket Lab Shares Soaring

June 9 - Rocket Lab USA Inc (NASDAQ:RKLB) shares climbed about 8% on Monday as investors reacted to a weekend spat between SpaceX CEO Elon Musk and former President Donald Trump. The feud began when Musk criticized Trump's proposed tax legislation on X, prompting Trump to suggest cutting Musk's government contracts. Musk fired back, hinting he might decommission SpaceX's Dragon spacecraft, currently the only U.S. vehicle for ferrying astronauts to the International Space Station, before retracting the comment. Over the weekend, Musk posted that we have got the spaceships, and they do not, implying U.S. reliance on SpaceX. That argument appears to be fueling interest in rival aerospace firms. RKLB, which holds multiple NASA contracts and is viewed as a contender for Trump's $175 billion Golden Dome missile defense initiative, saw its stock hit $31.21 in morning trading. AST SpaceMobile Inc (NASDAQ:ASTS) shares surged about 17% after reports suggested U.S. policymakers may look beyond SpaceX for various space investments. ASTS, a top customer of Blue Origin, inked a November launch deal with Jeff Bezos' company to deploy up to 45 satellites. Both RKLB and ASTS traded on above-average volume, signaling heightened investor focus on alternative space players amid the high-profile Musk-Trump clash. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Are Companies About to Dump Their Bitcoin? The Warning Signs Are Here
Are Companies About to Dump Their Bitcoin? The Warning Signs Are Here

Yahoo

time18 minutes ago

  • Yahoo

Are Companies About to Dump Their Bitcoin? The Warning Signs Are Here

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. The cryptocurrency landscape has witnessed a significant shift as corporations increasingly adopt bitcoin as a treasury asset. While this trend has contributed to bitcoin's recent price surge, it may also be creating new vulnerabilities in the market that warrant careful consideration. Corporate adoption of bitcoin has accelerated notably, with companies following the playbook pioneered by MicroStrategy (NASDAQ:MSTR). According to Bitcoin Treasuries data, 110 publicly listed companies globally now hold bitcoin, representing a substantial institutional commitment to the digital asset. Don't Miss: — no wallets, just price speculation and free paper trading to practice different strategies. Grow your IRA or 401(k) with Crypto – . Standard Chartered's analysis focuses on a refined sample of 61 companies that purchase bitcoin purely as a treasury holding, excluding industry participants like miners, exchanges, and service providers. This subset collectively owned nearly 674,000 bitcoins as of May's end—representing 3.2% of bitcoin's total 21 million coin supply. The numbers tell a compelling story: these 'bitcoin treasuries' have doubled their holdings over just two months, accumulating close to 100,000 additional bitcoins during this period. This buying pressure has been a key factor driving bitcoin to recent all-time highs. However, Standard Chartered's analysis reveals a concerning dynamic that could eventually reverse this supportive trend. Unlike Strategy, which accumulated bitcoin over time at various price points, many newer corporate entrants have purchased at significantly higher average prices. The bank's research suggests that approximately half of the monitored corporate treasuries would find themselves underwater if bitcoin fell below $90,000. This creates a potential domino effect where companies that entered the bitcoin treasury strategy during price peaks could become forced sellers during market downturns. The risk stems from several interconnected factors: Purchase Price Disparities: Most corporate treasuries in Standard Chartered's sample have average purchase prices well above Strategy's cost basis, making them more vulnerable to market volatility. NAV Multiple Justification: Currently, companies holding bitcoin trade at Net Asset Value multiples above 1, justified by market inefficiencies such as regulatory constraints and conservative institutional investment processes. As these barriers diminish over time, the premium valuations may compress. Corporate Pain Thresholds: Unlike dedicated cryptocurrency companies, traditional corporations may have lower tolerance for significant losses on treasury holdings. Standard Chartered estimates that newer entrants likely couldn't withstand a 50% decline from their average purchase price—a threshold that Strategy weathered during the 2022 crypto winter. Trending: New to crypto? on Coinbase. The analysis suggests that if bitcoin drops more than 22% below companies' average purchase prices, forced selling could emerge. This creates a feedback loop where price declines trigger corporate selling, potentially accelerating further declines. This dynamic differs markedly from Strategy's experience in November 2022, when bitcoin halved but the company maintained its position. Several factors may have aided Strategy's resilience: smaller absolute dollar losses at the time, the absence of U.S. spot bitcoin ETFs providing alternative exposure, and the company's fundamental commitment to bitcoin as a long-term strategy. This corporate treasury trend presents both opportunities and risks for the broader bitcoin market: Positive Factors: Corporate adoption provides institutional legitimacy and substantial buying pressure that has supported recent price appreciation. Risk Factors: The concentration of recent purchases at higher price levels creates potential selling pressure during market stress, possibly amplifying volatility. Timing Considerations: As market inefficiencies that currently justify premium valuations are resolved, bitcoin treasuries could shift from price supporters to sources of downside pressure. While corporate bitcoin adoption represents a significant maturation of the cryptocurrency market, investors should recognize that these treasury strategies may behave differently than those of dedicated bitcoin companies during market stress. The sustainability of this trend will likely depend on bitcoin's price stability and these companies' ability to maintain their positions through potential volatility. As Standard Chartered notes, the question isn't whether these companies will face pressure, but rather how much volatility they can withstand before strategic considerations shift. For market participants, understanding these dynamics becomes crucial as corporate treasuries represent an increasingly significant portion of bitcoin's circulating supply. Their behavior during the next major market downturn will provide important insights into the resilience of this newer form of institutional bitcoin adoption. Read Next: A must-have for all crypto enthusiasts: . Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Image: Shutterstock This article Are Companies About to Dump Their Bitcoin? The Warning Signs Are Here originally appeared on

Sharps Technology CEO, Robert Hayes, to Present at the Virtual Investor Summit on June 10, 2025
Sharps Technology CEO, Robert Hayes, to Present at the Virtual Investor Summit on June 10, 2025

Yahoo

time21 minutes ago

  • Yahoo

Sharps Technology CEO, Robert Hayes, to Present at the Virtual Investor Summit on June 10, 2025

Presentation to be webcast live at 10:00 AM ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: 'STSS' and 'STSSW') ('Sharps'), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart safety syringe products to the healthcare industry, today announced that Robert Hayes, CEO, will present at the Virtual Investor Summit on June 10, 2025, at 10:00 AM ET. Investors are invited to listen to the presentation and can register here. Sharps recently announced that the Company has commenced shipments under three customer orders tied to previously announced purchase agreements. These shipments represent the Company's first commercial deliveries and its transition to revenue-generating operations. All products are being manufactured and shipped from Sharps' facility in Hungary, which has undergone significant upgrades to support high-volume production. Read the update release HERE. Presentation Details: Event: Q2 Investor Summit Date & Time: 10:00 AM ET on June 10, 2025 Presenter: Robert Hayes, CEO Webcast: LINK HERE Conference Overview and Structure:The Investor Summit is an exclusive event tailored for investors focused on small- and micro-cap stocks. It offers a unique opportunity to meet with management teams from high-potential emerging companies, gain insights from industry experts, and understand how peers are navigating the current market environment. This quarter's event centers on micro-cap companies that are currently undervalued and positioned near catalyst events that could significantly accelerate their growth trajectory. Registration for Investors:To request free registration, please go to the Investor Summit website, ( and click the "Registration" button. For More Information, please visit: or, contact johnna-mae@ About Sharps Technology:Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary. For additional information, please visit FORWARD-LOOKING STATEMENTS:This press release contains 'forward-looking statements'. Forward-looking statements reflect our current view about future events. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan,' 'poised' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Investor Contact:Holdsworth PartnersAdam HoldsworthPhone: 917-497-9287Email: IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store